Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy

J Control Release. 2017 Jul 28:258:43-55. doi: 10.1016/j.jconrel.2017.05.006. Epub 2017 May 12.

Abstract

Two novel prodrug polymers POEG-b-PSSDas (redox-sensitive) and POEG-b-PCCDas (redox-insensitive), which consist of poly(oligo(ethylene glycol) methacrylate) (POEG) hydrophilic blocks and dasatinib (DAS, an oncogenic tyrosine kinases inhibitor) conjugated hydrophobic blocks, were designed as dual-functional carriers for codelivery with doxorubicin (DOX). Both carriers retained antitumor activity of DAS and could form mixed micelles with DOX. Compared to POEG-b-PCCDas micelles, incorporation of disulfide linkage into POEG-b-PSSDas micelles facilitated efficient cleavage of DAS from prodrug micelles in tumor cells/tissues, leading to a higher level of anti-tumor activity in vitro and in vivo. In addition, DOX-loaded POEG-b-PSSDas micelles exhibited triggered DOX release under a redox environment (10mM glutathione, GSH), and demonstrated enhanced cytotoxicity against 4T1.2 and PC3 cell lines compared to DOX and DOX-loaded POEG-b-PCCDas micelles. More importantly, DOX-loaded POEG-b-PSSDas micelles were more effective in inhibiting the tumor growth and prolonging the survival rate in an aggressive murine breast cancer model (4T1.2) compared to DOX-loaded POEG-b-PCCDas micelles and a micellar formulation co-loaded with DOX and DAS. This redox-responsive prodrug micellar system provides an attractive strategy for effective combination of tumor targeted therapy and traditional chemotherapy, which warrants further investigation.

Keywords: Co-delivery; Dasatinib; Doxorubicin; Prodrug micelles; Redox responsive.

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / pharmacokinetics
  • Antibiotics, Antineoplastic / therapeutic use
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Dasatinib / administration & dosage*
  • Dasatinib / pharmacokinetics
  • Dasatinib / therapeutic use
  • Delayed-Action Preparations / chemistry
  • Doxorubicin / administration & dosage*
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / therapeutic use
  • Drug Delivery Systems
  • Female
  • Humans
  • Mice, Inbred BALB C
  • Micelles
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Oxidation-Reduction
  • Polyethylene Glycols / chemistry
  • Prodrugs / administration & dosage*
  • Prodrugs / pharmacokinetics
  • Prodrugs / therapeutic use
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / pharmacokinetics
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Antibiotics, Antineoplastic
  • Delayed-Action Preparations
  • Micelles
  • Prodrugs
  • Protein Kinase Inhibitors
  • poly(ethylene glycol) methacrylate polymer
  • Polyethylene Glycols
  • Doxorubicin
  • Dasatinib